Chronic News and Research

RSS

Gilead announces results from Phase III clinical trial of Cayston, TIS in cystic fibrosis patients

Gilead Sciences, Inc. today announced that its head-to-head Phase III clinical trial of Cayston (aztreonam for inhalation solution) versus tobramycin inhalation solution (TIS) in cystic fibrosis (CF) patients with Pseudomonas aeruginosa (P. aeruginosa) achieved its co-primary endpoint of superiority of Cayston for mean actual change in forced expiratory volume in one second (FEV1, a measure of lung function) percent predicted across three treatment cycles (six months).

22 Oct 2010

TOBI reduces mortality in patients with cystic fibrosis, Pa lung infection

A new analysis of data from more than 12,000 people with cystic fibrosis (CF) and Pseudomonas aeruginosa (Pa) lung infection in the Cystic Fibrosis Foundation's Patient Registry shows that use of TOBI (Tobramycin Inhalation Solution, USP) was associated with a 21% reduction in mortality in the following year.

22 Oct 2010

Experts agree on key policy recommendations for management, prevention of rheumatic, MSKD

On 19 October 2010, experts from academia, scientific societies, patient organisations, Member States' government and social security institutions as well as EU bodies agreed upon a number of key policy recommendations for improving the management and prevention of rheumatic and musculoskeletal diseases.

22 Oct 2010

CIHR, RX&D - HRF to fund research projects on mental illness, palliative care

Six research projects on co-existing heath problems associated with mental illness and one project on palliative care among First Nations received over $9 million in funding announced today. This amount is provided by the Canadian Institutes of Health Research and the Rx&D Health Research Foundation.

22 Oct 2010

Biomarkers can improve ability to identify patients at high risk of CKD: Study

Measuring three biomarkers in a single blood sample may improve physicians' ability to identify patients at high risk of developing chronic kidney disease, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology.

22 Oct 2010

Clinical research scholar receives grant to promote lifestyle changes for HIV patients

Between the demands of work, family and friends, many women find health takes a back seat. Women with HIV are no exception. "Many women with the HIV face challenges from sleepless nights to little personal time-all activities that can negatively impact health," says Allison Webel, a clinical research scholar and instructor at the Frances Payne Bolton School of Nursing at Case Western Reserve University.

22 Oct 2010

Celtic Pharma receives US patent for methods to treat breast, colon cancer

Celtic Pharmaceutical Holdings L.P. today announced that the U.S. Patent Office has issued U.S. patent 7,816,323, for novel methods to treat breast and colon cancers using a combination therapy of Xerecept with Avastin.

22 Oct 2010

Oral cancer linked to oral sex: Study

Swedish researchers have found that the Human papillomavirus (HPV) that causes cervical cancer in women is also a risk factor for oropharyngeal squamous cell carcinoma (OSCC) or oral and throat cancer in men even if they do not smoke or consume alcohol.

21 Oct 2010

Australian stem cell line offers fresh approach to diabetes cure

Australian researchers have developed the country’s first diabetes specific stem cell line, a major advance for patients suffering from the chronic disease.

21 Oct 2010

Boston Scientific's Advanix Biliary Plastic Stents receive FDA 510(k) clearance and CE Mark approval

Boston Scientific Corporation today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration and CE Mark approval to market its Advanix™ Biliary Plastic Stents for the treatment of biliary strictures, including biliary stone disease, benign biliary strictures, and suspected and confirmed malignancies in the biliary system. The product is now available in Europe and other international markets; the Company plans to launch it in the U.S. this quarter.

21 Oct 2010

Health Canada approves ULORIC to lower serum uric acid levels in patients with gout

Takeda Canada, Inc. is pleased to announce that ULORIC® (febuxostat), an innovative oral urate-lowering therapy to lower serum uric acid levels in patients with gout is now available in Canada. This medication is the first new treatment option in more than 40 years for the approximately three per cent of Canadians who have hyperuricemia associated with gout.1 ULORIC was discovered by Teijin Pharma Limited of Tokyo and licensed to Takeda for the Canada market.

21 Oct 2010

Genmab A/S reports DKK 78 million in net sales for Arzerra

Genmab A/S announced today that the net sales for Arzerra(R) (ofatumumab) during the third quarter of 2010 were approximately DKK 78 million (approximately USD 14 million).

21 Oct 2010

Researcher creates novel theory about chronic depression

Chronic depression is an adaptive, reparative neurobiological process gone wrong, say two University of California, San Diego School of Medicine researchers, positing in a new theory that the debilitating mental state originates from more ancient mechanisms used by the body to deal with physical injury, such as pain, tissue repair and convalescent behavior.

21 Oct 2010

$OptiNose reports positive results from study of fluticasone delivered by novel device in refractory CRS$

OptiNose reports positive results from study of fluticasone delivered by novel device in refractory CRS

Today OptiNose Inc. announced the positive results of a study evaluating the efficacy of fluticasone when delivered by the Company's novel bi-directional technology in patients with refractory chronic rhinosinusitis (CRS). The results of the study have been published in an article in the September issue of Rhinology.

21 Oct 2010

Empire announces launch of Patient Centered Medical Home pilot

For many people with chronic health conditions, it can be tough to navigate through the complex healthcare system. Mary, a 65 year old woman with several conditions including diabetes, arthritis, high blood pressure and high cholesterol, visits specialists for each of these conditions - an endocrinologist, rheumatologist and cardiologist - in addition to her primary care physician.

21 Oct 2010

Protein IL-37 could help treat inflammatory diseases in adults and children

A husband and wife research team from Melbourne, Australia, have identified a protein that may be a key therapy for many inflammatory diseases, including those affecting premature babies.

21 Oct 2010

Intercell and Romark announce IC41-nitazoxanide combination clinical trials for HCV

Intercell AG and Romark Laboratories L.C. today announced plans to commence clinical trials of Intercell's investigational therapeutic Hepatitis C virus (HCV) vaccine, IC41, in combination with Romark's antiviral drug, nitazoxanide, during the first half of 2011.

21 Oct 2010

Study finds black rice bran may reduce inflammation

Scientists are reporting evidence that black rice a little-known variety of the grain that is the staple food for one-third of the world population may help soothe the inflammation involved in allergies, asthma, and other diseases.

21 Oct 2010

Quark initiates dosing NAION patients in QPI-1007 Phase I study for ocular neuroprotection

Quark Pharmaceuticals, Inc., a pharmaceutical company engaged in the discovery and development of RNAi-based therapeutics, today announced it has dosed the first patient with recent onset of non-arteritic anterior ischemic optic neuropathy (NAION) in its ongoing Phase I study of QPI-1007, the Company's proprietary synthetic siRNA drug candidate for ocular neuroprotection.

21 Oct 2010

Study on health effects of alcohol consumption with HIV

Living with HIV is difficult under the best of circumstances, but for people carrying the virus, alcohol consumption can become particularly perilous in intricate ways that are only beginning to be understood. At the Brown Alcohol Research Center on HIV (ARCH) funded by a new $7.5-million, five-year grant from the National Institutes of Health, Brown University scientists will study the health effects of drinking with HIV and provide doctors and patients with the latest guidance their results suggest.

21 Oct 2010

Chronic News and Research

Gilead announces results from Phase III clinical trial of Cayston, TIS in cystic fibrosis patients

TOBI reduces mortality in patients with cystic fibrosis, Pa lung infection

Experts agree on key policy recommendations for management, prevention of rheumatic, MSKD

CIHR, RX&D - HRF to fund research projects on mental illness, palliative care

Biomarkers can improve ability to identify patients at high risk of CKD: Study

Clinical research scholar receives grant to promote lifestyle changes for HIV patients

Celtic Pharma receives US patent for methods to treat breast, colon cancer

Oral cancer linked to oral sex: Study

Australian stem cell line offers fresh approach to diabetes cure

Boston Scientific's Advanix Biliary Plastic Stents receive FDA 510(k) clearance and CE Mark approval

Health Canada approves ULORIC to lower serum uric acid levels in patients with gout

Genmab A/S reports DKK 78 million in net sales for Arzerra

Researcher creates novel theory about chronic depression

OptiNose reports positive results from study of fluticasone delivered by novel device in refractory CRS

Empire announces launch of Patient Centered Medical Home pilot

Protein IL-37 could help treat inflammatory diseases in adults and children

Intercell and Romark announce IC41-nitazoxanide combination clinical trials for HCV

Study finds black rice bran may reduce inflammation

Quark initiates dosing NAION patients in QPI-1007 Phase I study for ocular neuroprotection

Study on health effects of alcohol consumption with HIV

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News